Is There a Wegovy Equivalent Available in the UK?

The myth: there's a generic or cheaper version of Wegovy you can switch to

This is the most common misunderstanding behind the search. In the UK, semaglutide for weight management is a branded prescription medicine (Wegovy) made by Novo Nordisk. There is no licensed generic semaglutide for weight loss available from a UK pharmacy, and there is no compounded or biosimilar version that holds a UK marketing authorisation for this indication. If you've seen products marketed that way, that is a serious red flag rather than a discovery.

The confusion partly comes from Ozempic, which also contains semaglutide and is made by the same manufacturer. Ozempic is licensed in the UK for type 2 diabetes. Using it for weight loss is off-label, and the NHS semaglutide guidance is clear that Wegovy and Ozempic are not interchangeable prescriptions. A prescriber working within good clinical practice won't simply swap one for the other to manage cost. What the term "Wegovy equivalent" more legitimately refers to is a different licensed medicine that works in a related way, which brings us to tirzepatide.

It is understandable to want a cheaper route. These treatments represent a real outlay, and many people arrive at this search having already been told the NHS waiting list is long. That frustration is legitimate. The useful answer is to understand what options genuinely exist, not what the internet implies exists.

Tirzepatide (Mounjaro): the closest comparison, with meaningful differences

Mounjaro is frequently described as a semaglutide equivalent or a Wegovy equivalent in clinical discussions. They are related but not the same. Wegovy works on the GLP-1 receptor; Mounjaro works on both the GLP-1 and GIP receptors, making it the only dual-agonist weight-loss medicine currently licensed in the UK. Both are once-weekly injections. Both are licensed for adults with a BMI of 30 or above, or 27 or above alongside a weight-related health condition such as high blood pressure or type 2 diabetes.

The SURMOUNT-5 trial (a direct head-to-head comparison published in the New England Journal of Medicine in 2025) found that tirzepatide produced greater average weight reduction than semaglutide 2.4mg over 72 weeks in adults with obesity who did not have diabetes. NICE's appraisal of tirzepatide, TA1026, discusses these findings and notes that indirect comparisons across trials also favour tirzepatide. That does not make Mounjaro right for every person. Tolerability, existing health conditions, how you feel about injections and what dose you may need are all part of a clinical conversation, not a spreadsheet comparison.

You can read more about how the injection and its dose schedule work on the Wegovy overview page and the corresponding weight-loss treatments page.

Oral semaglutide: a Wegovy equivalent without a needle

If the search for a Wegovy equivalent is really a search for a needle-free option, the answer changed in summer 2026. On 11 June 2026 the MHRA approved Wegovy tablets (oral semaglutide co-formulated with an absorption enhancer called SNAC) as the first oral GLP-1 medicine licensed in the UK for weight management. The UK was the first country in Europe to receive this approval.

The active ingredient is identical to the injection: semaglutide. The dosing ladder is different, 1.5mg, 4mg, 9mg, rising to a 25mg maintenance dose, taken once daily on an empty stomach at least 30 minutes before food or other medicines. Clinical trial data (OASIS 4, 64 weeks) showed average weight loss of around 13.6% versus approximately 2.4% for placebo, with roughly 17% average loss among participants who adhered fully to the schedule. Wegovy tablets require no refrigeration, which some people find genuinely useful for travel or daily routine, and you can find the full details on the Wegovy tablets page. They are a private prescription at launch; NICE has not yet appraised them.

If cost is part of the decision, Wegovy pricing in the UK explains what a legitimate private prescription typically includes and why headline prices vary between providers.

Which semaglutide equivalent is right for you, and how that gets decided

The honest answer is that a prescriber decides, not a webpage. The medicines in this space (Wegovy injection, Wegovy tablets, Mounjaro) share a general mechanism but differ in receptor targets, dose schedules, formulation and the trial evidence behind them. NICE has separate technology appraisals for tirzepatide and injectable semaglutide. Neither appraisal covers oral semaglutide yet.

For people accessing treatment privately, the clinical assessment matters as much as the medicine choice. At nume, a GPhC-registered Independent Prescriber reads every consultation personally on the day it arrives, your eligibility, medical history and current medications all feed into which treatment, if any, is appropriate. People who are already on a dose they want to understand better can find dose-specific information on the lower dose pages. Those thinking about whether treatment is right at all will find the frequently asked questions a useful starting point.

Our clinical team brings this same scrutiny to transfer patients and to anyone requesting a dose change, the decision sits with a real person, not a rule engine. If you'd like to explore which option suits your situation, check your eligibility with a free consultation.